Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...

and interleukin-2 (IL-2). Next, the authors investigated the mechanism of loss of tolerance induction by LSECs exposed to high concentrations of antigen. The effect was not dependent on ...

The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer’s. Also Read: EXCLUSIVE ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial ...

Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors in patients with unresectable locally ...

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...